Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3284810.26442/terarkh2018902105-111Editorial articleПередовая статьяReview ArticleOptimizing therapy of liver diseases not associated with viral infectionОптимизация терапии заболеваний печени, не ассоциированных с вирусной инфекциейSvistunovA AСвистуновАндрей Алексеевич

член-корр. РАН, д.м.н., проф., первый проректор Первого МГМУ им. И.М. Сеченова. https://orcid.org/ 0000-0003-1592-5703

OsadchukM AОсадчукМихаил Алексеевич

д.м.н., проф., зав. каф. поликлинической терапии лечебного факультета Первого МГМУ им. И.М. Сеченова. http://orcid.org/0000=0003=0485=6802

osadchuk.mikhail@yandex.ruKireevaN VКирееваНаталья Викторовна

к.м.н., доц. каф. поликлинической терапии лечебного факультета Первого МГМУ им. И.М. Сеченова. https://orcid.org/0000-0002-3467-886X

OsadchukM MОсадчукМаксим Михайлович

к.м.н., зав. отд. организационно-методической и клинико-экспертной работы Городской поликлиники №52

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)City Polyclinic No. 52, Moscow Healthcare DepartmentГБУЗ г. Москвы «Городская поликлиника №52» ДЗ г. Москвы15022018902VOL 90, NO2 (2018)ТОМ 90, №2 (2018)949911042020Copyright ©; 2018, Consilium MedicumCopyright ©; 2018, ООО "Консилиум Медикум"2018Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/32848

The review demonstrated results and prospects of non-pharmacological and drug therapy patients with liver disease, not associated with a viral infection. The presented data emphasize the relevance of studying the problem of effective therapy of diseases of the liver and its role in improving the course and outcomes of liver disease.

В обзоре продемонстрированы итоги и перспективы нелекарственной и лекарственной терапии больных с заболеваниями печени, не ассоциированными с вирусной инфекцией. Представленные данные подчеркивают актуальность изучения проблемы эффективной терапии заболеваний печени и ее роль в улучшении течения и исходов патологии печени.

non-alcoholic and alcoholic fatty liver diseasenon-pharmacological and pharmacological therapyнеалкогольная и алкогольная жировая болезнь печенинемедикаментозная и медикаментозная терапияMokdad A.H, Marks J.S, Stroup D.F, Gerberding J.L. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-45. doi: 10.1001/jama.291.10.1238Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol - use disorders. Lancet. 2009;373(9682):2223-33. doi: 10.1016/s0140-6736(09)60746-7World Health Organization. Global status report on alcohol and health 2014 [Available from: http://www.who.int/substance_abuse/publications/global_alcohol_report/en/].Poynard T, Mathurin P, Lai C, Guyader D, Poupon R, Tainturier M.H, Myers R, Muntenau M, Ratziu V, Manns M, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257-65. doi: 10.1016/s0168-8278(02)00413-0Younossi Z.M, Koenig A.B, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - Meta - analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi: 10.1002/hep.28431Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta - analysis. J Gastroenterol Hepatol. 2016;31:936-44. doi: 10.1111/ jgh.13264Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-93. doi: 10.3748/wjg.v22.i44.9674Rowell R, Anstee Q. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clin Med. 2015;15 Suppl 6:s77-s82. doi: 10.7861/clinmedicine.15-6-s77Charlton M.R, Burns J.M, Pedersen R.A, Watt K.D, Heimbach J.K, Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141(4):1249-53. doi: 10.1053/j.gastro.2011.06.061Day C, Anstee Q. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 2015;35:270-90. doi: 10.1055/s-0035-1562947Chamorro A, Torres J, Mirón-Canelo J, González-Sarmiento R, Laso F, Marcos M. Systematic review with meta - analysis: the I148M variant of patatin - like phospholipase domain - containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Alimentary Pharmacol Therapeut. 2014;40:571-81. doi: 10.1111/apt.12890Sookoian S, Pirola C.J. Meta - analysis of the influence of I148M variant of patatin - like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883-94. doi: 10.1002/hep.24283Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke H, Hamza S, Corradini S, Burza M, Guyot E, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta - analysis of individual participant data. Hepatology. 2014;59(6):2170-7. doi: 10.1002/hep.26767Issa D, Wattacheril J, Sanyal A.J. Treatment options for nonalcoholic steatohepatitis - a safety evaluation. Expert Opin Drug Safety. 2017 Aug;16(8):903-13. doi: 10.1080/14740338.2017.1343299Mathurin P, O’Grady J, Carithers R, Phillips M, Louvet A, Mendenhall C, Ramond M, Naveau S, Maddrey W, Morgan T. Corticosteroids improve short - term survival in patients with severe alcoholic hepatitis: meta - analysis of individual patient data. Gut. 2010;60(2):255-60. doi: 10.1136/gut.2010.224097Fialla A, Israelsen M, Hamberg O, Krag A, Gluud L. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta - analysis. Liver Intern. 2015;35(9):2072-8. doi: 10.1111/liv.12798Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25(1): 108-11. doi: 10.1002/hep.510250120Hutchinson S, Bird S, Goldberg D. Influence of alcohol on the progression of hepatitis C virus infection: A meta - analysis. Clin Gastroenterol Hepatol. 2005;3(11):1150-9. doi: 10.1016/s1542-3565(05)00407-6Chen C, Yoon Y, Yi H, Lucas D. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcoholism: Clin Exper Res. 2007;31(2):285-92. doi: 10.1111/j.1530-0277.2006.00304.xHarris D, Gonin R, Alter H, Wright E, Buskell Z, Hollinger F, Seeff L. The Relationship of Acute Transfusion-Associated Hepatitis to the Development of Cirrhosis in the Presence of Alcohol Abuse. Ann Intern Med. 2001;134(2):120-4. doi: 10.7326/0003-4819-134-2-200101160-00012Tsui J, Pletcher M, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol - related problems. J Hepatol. 2006;44(2):262-6. doi: 10.1016/j.jhep.2005.07.027Lucey M, Mathurin P, Morgan T. Alcoholic hepatitis. New Engl J Med. 2009;360(26):2758-69. doi: 10.1056/nejmra0805786Mathurin P, Mendenhall C.L, Carithers R.L. Jr, Ramond M.J, Maddrey W.C, Garstide P, Rueff B, Naveau S, Chaput J.C, Poynard T. Corticosteroids improve short - term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36(4):480-7. doi: 10.1016/s0168-8278(01)00289-6Raetsch C, Jia J, Boigk G, Bauer M, Hahn E, Riecken E, Schuppan D. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50(2):241-7. doi: 10.1136/gut.50.2.241Assimakopoulos S, Thomopoulos K, Labropoulou-Karatza C. Pentoxifylline: A first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol. 2009;15(25):3194-5. doi: 10.3748/wjg.15.3194Mc Clain C, Hill D, Barve S. Infliximab and prednisolone: Too much of a good thing? Hepatology. 2004;39(6):1488-90. doi: 10.1002/ hep.20267Felver M, Mezey E, Mc Guire M, Mitchell M, Herlong H, Veech G, Veech R. Plasma Tumor Necrosis Factor alpha Predicts Decreased Long-Term Survival in Severe Alcoholic Hepatitis. Alcoholism: Clin Exper Res. 1990;14(2):255-9. doi: 10.1111/j.1530-0277.1990.tb00482.xYin M, Wheeler M, Kono H, Bradford B, Gallucci R, Luster M, Thurman R. Essential role of tumor necrosis factor alpha in alcohol - induced liver injury in mice. Gastroenterology. 1999;117(4):942-52. doi: 10.1016/s0016-5085(99)70354-9Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet M, Davion T, Oberti F, Broët P, Emilie D. A double - blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39(5):1390-7. doi: 10.1002/hep.20206Stadlbauer V, Mookerjee R, Hodges S, Wright G, Davies N, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008;48(6):945-51. doi: 10.1016/j.jhep.2008.02.015Kirpich I, Solovieva N, Leikhter S, Shidakova N, Lebedeva O, Sidorov P, Bazhukova T, Soloviev A, Barve S, Mc Clain C, Cave M. Probiotics restore bowel flora and improve liver enzymes in human alcohol - induced liver injury: a pilot study. Alcohol. 2008;42(8):675-82. doi: 10.1016/j.alcohol.2008.08.006Vlachogiannakos J, Saveriadis A, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis D. Intestinal decontamination improves liver haemodynamics in patients with alcohol - related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29(9):992-9. doi: 10.1111/j.1365-2036.2009.03958.xMichelena J, Altamirano J, Abraldes J, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-Pagán J, Fernández J, Arroyo V, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology. 2015;62(3):762-72. doi: 10.1002/hep.27779Zhang Z, Wang F. Stem cell therapies for liver failure and cirrhosis. J Hepatol. 2013;59(1):183-5. doi: 10.1016/j.jhep.2013.01.018Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S. Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis. Cell Stem Cell. 2012;10(5):544-55. doi: 10.1016/j.stem.2012.03.007Aurich H, Sgodda M, Kaltwasser P, Vetter M, Weise A, Liehr T, Brulport M, Hengstler J, Dollinger M, Fleig W, Christ B. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut. 2009;58(4):570-81. doi: 10.1136/gut.2008.154880Kuo T, Hung S, Chuang C, Chen C, Shih Y, Fang S, Yang V, Lee O. Stem Cell Therapy for Liver Disease: Parameters Governing the Success of Using Bone Marrow Mesenchymal Stem Cells. Gastroenterology. 2008;134(7):2111-21.e3. doi: 10.1053/j.gastro.2008.03.015Jang Y, Kim Y, Baik S, Kim M, Eom Y, Cho M, Park H, Park S, Kim B, Kim J, et al. Histological improvement following administration of autologous bone marrow - derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver International. 2014;34(1):33-41. doi: 10.1111/liv.12218Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, et al. Improved Liver Function in Patients with Liver Cirrhosis After Autologous Bone Marrow Cell Infusion Therapy. Stem Cells. 2006;24(10):2292-8. doi: 10.1634/stemcells.2005-0542Ismail A, Fouad O, Abdelnasser A, Chowdhury A, Selim A. Stem Cell Therapy Improves the Outcome of Liver Resection in Cirrhotics. J Gastrointestin Cancer. 2010;41(1):17-23. doi: 10.1007/s12029-009-9092-9Singh S, Osna N, Kharbanda K. Treatment options for alcoholic and non - alcoholic fatty liver disease: A review. World J Gastroenterol. 2017;23(36):6549-70. doi: 10.3748/wjg.v23.i36.6549EASL-EASD-EASO Clinical Practice Guidelines for the management of non - alcoholic fatty liver disease. Diabetologia. 2016 Jun; 59(6):1121-40. doi: 10.1007/s00125-016-3902-yИвашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О., Драпкина О.М., Шульпекова Ю.О., Цуканов В.В., Маммаев С.Н., Маев И.В., Пальгова Л.К. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2): 24-42.Takahashi Y, Sugimoto K, Inui H, Fukusato T.Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(13):3777-85. doi: 10.3748/wjg. v21.i13.3777Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K, Charlton M, Sanyal A. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6):2005-23. doi: 10.1002/hep.25762Lewis J.D, Ferrara A, Peng T, Hedderson M, Bilker W, Quesenberry C, Vaughn D, Nessel L, Selby J, Strom B. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-22. doi: 10.2337/ dc10-1068Lomonaco R, Sunny N, Bril F, Cusi K. Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. Drugs. 2013;73(1):1-14. doi: 10.1007/s40265-012-0004-0Haukeland J, Konopski Z, Eggesbø H, von Volkmann H, Raschpichler G, Bjøro K, Haaland T, Løberg E, Birkeland K. Metformin in patients with non - alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853-60. doi: 10.1080/ 00365520902845268Lavine J, Schwimmer J, van Natta M, Molleston J, Murray K, Rosenthal P, Abrams S, Scheimann A, Sanyal A, Chalasani N, et al. Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA. 2011;305(16):1659-68. doi: 10.1001/jama.2011.520Strange R, Shipman K, Ramachandran S. Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes. 2015;6(7):896-911. doi: 10.4239/wjd.v6.i7.896Katiyar S.K. Silymarin and skin cancer prevention: Anti - inflammatory, antioxidant and immunomodulatory effects (Review). Intern J Oncol. 2005;26:169-76. doi: 10.3892/ijo.26.1.169Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29(3):447-63. doi: 10.1007/s10555-010-9237-0Lee J, Kim S, Kim H, Lee T, Jeong Y, Lee C, Yoon M, Na Y, Suh D, Park N, et al. Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells. J Cell Physiol. 2007;210(2):385-97. doi: 10.1002/jcp.20852Anon (2017) [online]. Available at: http://Al-Jassabi S, Saad A, Azirun M.S, Al-Omari A. The role of Silymarin in prevention of Alloxan - induced diabetes mellitus in Balb/C mice. American-Eurasian J Toxicol Sci. 2011;3(3):172-6 [Accessed 29 Nov. 2017].Anon (2017) [online]. Available at: http://WHO monographs on selected medicinal plants. Fructus Silybi Mariae. Vol. 2. Geneva: World Health Organization; 2002. P. 300-16 [Accessed 29 Nov. 2017].Malihi F, Hosseini-Tabatabaei A, Esmaily H, Khorasani R, Baeeri M, Abdollahi M. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus. Open Life Sci. 2009;4(3):369-80. doi: 10.2478/s11535-009-0014-4Liu J, Zhang M, Wang W, Grimsgaard S. Chinese herbal medicines for type 2 diabetes mellitus. Cochrane Database System Rev. 2002. doi: 10.1002/14651858.cd003642.pub2Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non - alcoholic fatty liver disease. World J Gastroenterol. 2014;20(26):8341-50. doi: 10.3748/ wjg.v20.i26.8341Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biol Med. 2012;52(9):1658-65. doi: 10.1016/j.freeradbiomed.2012.02.008Marin V, Gazzin S, Gambaro S, Dal Ben M, Calligaris S, Anese M, Raseni A, Avellini C, Giraudi P, Tiribelli C, Rosso N. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non - alcoholic Steatohepatitis. Nutrients. 2017;9(9):1006. doi: 10.3390/ nu9091006Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Medica. 2012;78(13):1458-77. doi: 10.1055/s-0032-1315117Fan J, Jia J, Li Y, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. J Digest Dis. 2011;12(1):38-44. doi: 10.1111/j.1751-2980.2010.00476.xCharlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner R.H, Rosen C.B, Batts K.P. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplantation. 2001;7(7):608-14. doi: 10.1053/jlts.2001.25453